Clinical characteristics and viral markers in 19 cases of HBV-DNA (+) hepatocellular carcinoma Table 3 Clinical characteristics and viral makers in 6 cases of and-HCV (-) and HBsAg (-) hepatocellular carcinoma 19 patients in whom HBV-DNA was detected. The difference in transfusion history between the HBsAg-positive patients (20.0% [2/10] ) and the HBsAg-negative patients (22.2% [2/9]) was not significant. HBe antigen was detected in only 2 of the 10 HBsAg-positive patients. Anti-HCV was detected in 40% (4/10) and 100% (9/9) of the HBsAg-positive and -negative patients, respectively. 4) Background factors of the patients in whom HBsAg, HBV DNA or and-HCV was not detected Six (5.6%) of the 108 patients were negative for HBsAg, HBV DNA and anti-HCV. The mean age of these 6 patients at the time of diagnosis of HCC was 56.7 years, and they consisted of 5 males and 1 female. Two had a family history of chronic hepatic disease. None of the 6 patients had a long history of alcohol consumption. Only one had a history of transfusion. Three of the 6 patients were positive for anti-HBs and HBc antibody (Table 3) .
Discussion
In Japan 80% or more of HCC patients without HBsAg are positive for anti-HCV, and in this study, anti-HCV was detected in 88.8% of the subjects, suggesting that HCV is extremely important in the pathogenesis of HCC.
In Japan, many HCC patients without HBsAg have detectable anti-HBc and anti-HBs suggesting that HBV may be involved in carcinogenesis even in HCC patients without HBsAg. Sakamoto et al. have recently reported that HBV DNA can be detected by Southern blot analysis in some patients who are sero negative for HBsAg (9) .
We investigated the frequency of serum HBV DNA detection in HCC patients who tested negative for HBsAg. HBV DNA was detected by PCR in 9 (9.2%) of 98 HCC patients who were seronegative for HBsAg. Eight of the 9 patients were positive for anti-HBC. HBV DNA was detected in 29.6% of the HBsAg-negative HCC patients with positive serologic tests for anti-HBc and negative tests for anti-HBs. Thus, the frequency of detection of HBV DNA in serum was high, even in HCC patients without HBsAg, particularly in patients who were positive for anti-HBc and negative for anti-HBs. These results suggest that HBV may be involved in the pathogenesis of HCC in this subset of patients. The HBV carrier state in Japan is believed to be caused by mother-child infection or infection in childhood. The present study also revealed that the proportion of HBV DNA-positive patients with a family history of chronic hepatic disease was significantly (p <0.05) higher than among HBV DNA-negative patients. Furthermore, 13 of the 19 patients (68.4%) in whom HBV DNA was detected were positive for anti-HCV. Superinfection of an HBV carrier with HCV probably occurred in these 13 patients. According to Notumata et al. 10, 11) , because of viral interference, superinfection with HBV and HCV induces less HBV proliferation than single infection with HBV, and the HBsAg titer is believed to decrease as a results. Anti-HCV was detected in all of the HBsAg-negative patients in whom HBV DNA was detected. HBsAg was not detected despite the detection of HBV DNA in the serum, probably because the amount of HBsAg had decreased below the sensitivity of the assay because of interference between HBV and HCV.
Tests for HBV DNA, HBsAg and anti-HCV were negative in 6 (5.5%) of the 108 patients , and alcoholic liver disease was clinically excluded in these 6 cases. Anti-HBs and anti-HBc were detected in 2 of these cases. Since HCV RNA was not determined in this study, we cannot exclude the possibility of hepatitis C infection in these patients. Additional studies on these 6 patients will be necessary to determine whether hepatitis C or non-C, non-B hepatitis is associated with their cancer .
